Researchers at Cold Spring Harbor Laboratory have pinpointed a single protein that, when blocked, improved memory and learning in mice engineered to mimic Alzheimer's disease. The discovery centers on PTP1B, a protein that Nicholas Tonks first identified nearly four decades ago and has now linked to the disease's progression.
The team found that PTP1B plays a crucial role in controlling how the brain's immune cells function. When disabled, these immune cells become more efficient at clearing away amyloid-beta plaques, the toxic protein clumps that accumulate in Alzheimer's brains and are thought to destroy neurons.
"Over the course of the disease, these cells become exhausted and less effective," said graduate student Yuxin Cen, one of the researchers. "Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques." Microglia are the brain's cleanup crew, responsible for removing debris and damaged material. The new work shows they rely on a protein called SYK to do their job, and that PTP1B normally dampens SYK signaling.
Tonks, whose own mother lived with Alzheimer's, describes the disease as "a slow bereavement" where patients are "lost piece by piece." The personal connection drives his mission to find effective treatments for millions worldwide.
Current Alzheimer's drugs focus narrowly on reducing amyloid buildup, but their benefits plateau quickly for many patients. Postdoctoral fellow Steven Ribeiro Alves suggested that a dual approach could work better. "Using PTP1B inhibitors that target multiple aspects of the pathology, including Aβ clearance, might provide an additional impact," he said.
The link between Alzheimer's and metabolic disease strengthens the case for pursuing this target. Obesity and type 2 diabetes are recognized risk factors for cognitive decline, and PTP1B is already under investigation as a potential treatment for these conditions. A single drug that addresses both metabolic and neurological pathways could open new treatment avenues.
Tonks and his colleagues are now working with DepYmed, Inc. to develop PTP1B inhibitors. The vision is to combine these new drugs with existing approved Alzheimer's medications to slow disease progression and improve patient quality of life. Clinical testing remains years away, but the research narrows the gap between laboratory discovery and bedside application.
Author Jessica Williams: "This shifts the conversation from single-target therapy to a more sophisticated approach that tackles the disease from multiple angles at once."
Comments